ESMO 2023

5 year follow-up

DATO-DX - where is it going?

Preoperative checkpointinihition in ER+ disease

Highlights in eBC

Remarkable efficacies in patients with HER2+ mBC with brain metastases

My highlights of ESMO23 in metastatic breast cancer

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining first-line standard of care in mUC!

Clearing up non-clear cell RCC

Early use of enzalutamide in advanced prostate cancer

Lu-PSMA leads forward

New 3rd line therapy for RCC

ALINA - immediate change of practice!

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

My highlights from ESMO 2023

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Tarlatamab in SCLC

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What is your definition of triple-negative breast cancer?

What was the most exciting news at ESMO23?

New and better biomarkers are needed!

Anticipated updates and exciting new data for checkpointinhibitors

Immunoncology in eBC - triple negative and more?

MonarchE - trial update

Our guidelines are correct

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Pembrolizumab solidifies as SOC in early-stage TNBC

Highlights in eBC

Carry-over effects in monarchE confirmed

HR+ study with > 20 % PCR

My highlights of ESMO23 in early breast cancer

Preoperative checkpointinihition in ER+ disease

Consolidation of data in early HR+ and triple-negative breast cancer

Clinically relevant effect of pembro also in PCR

New data on neoadjuvant immunotherapy

Analysis of tumour microenvironment and immunophenotype in TNBC

Use of immunotherapy in the perioperative setting of luminal Her2- BC

Detailed view of nodal-negative patients

ER-low corresponds diagnostically to ER-0 breast cancer

Negative EFS results from NeoTrip

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Ribociclib effective in all subtypes

5 year follow-up

Punti salienti in eBC

Studio NeoTrip: negativi i risultati

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

MonarchE - mise à jour de l'essai

Nouvelles données sur l'immunothérapie néoadjuvante

What was the most exciting news at ESMO23?

Improvement of therapy outcome by app-based patient education

How to organize a molecular tumorboards in breast cancer?

New targets, new linker, new ADCs - much more to learn with new therapies!

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

New ADC for metastatic breast cancer?

T-DXd also effective for brain metastases

My highlights of ESMO23 in metastatic breast cancer

Highlights in mBC

T-DXd in HER2+ patients with brain metastases

Robust data from the monarchE

HER2DX in the PHERgain trial

DATO-DX - where is it going?

Patient-centered molecular medicine - a new approach

Benefit for SG even after intensive pretreatment

Dato-DXd - new player in advanced luminal disease

New ADC in HR+ disease

Can surgery be spared following primary systemic therapy?

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Fulvestran better than anastrozole, but no survival benefit

T-DXd - new standard of care for brain mets?

OP seems to be dispensable for super responders

TROP2 expression as a potential mechanism of resistance in HER2+ patients

Still on track for success in HER2-low MBC

Even more new generation ADCs in breast cancer?

Improved oncological therapy with the smartphone

HS20089 - a novel ADC is coming for TNBC

TULIP: Trastuzumab duocarmazine without OS benefit

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

ADC + Immunotherapy - the BEGONIA study paradigm

Duvalumab + Dato-DXd effective

Abemaciclib remains consistent in 5-year follow-up

Our guidelines are correct

Lo studio BEGONIA nelle paziento con tumore triplo negativo

Punti salienti in mBC

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

HER2DX en el estudio PHERgain

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust data is needed.

What is the future of immune therapy in prostate cancer?

Lu-PSMA leads forward

Combination of radioligand therapy with chemotherapy useful

Immunotherapy in metastatic PCa

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

EMBARK expands ENZA indication to PCa

Embark without fear

EMBARK - Quality of Life

Osteoprotection at mHSPC

RADICALS RT: Trial and controversies

PSMAfore unleashes urooncologic opportunity

Negative data for pembrolizumab in mHSCPC & mCRPC

TITAN: ultra-low PSA = best prognosis

Brave New World in mCRPC

Big data and AI prediction tools

Precision medicine at mCRCP

Early use of enzalutamide in advanced prostate cancer

Longterm toxicity of adjuvant RT after prostatectomy

PSMA FORE: Trial and controversies

ENZA P:Trial and controversies

IO therapy in metastatic prostate cancer.

Salvage radiotherapy the new standard

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

CXCR2 inhibitor in PCa

STAMPEDE data. Skelettstärkande och riskstratifiering.

EMBARK och livskvalitet

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

CXCR2 hämmare och prostatacancer

Immunterapi vid prostatacancer

Big Data och AI för prediktion vid prostatacancer

Part 2: New standard of care in first line urothelial cancer!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

Part1: New standard of care in first line urothelial cancer?!

DAD, DAD-IO

FGFR inhibitors: What is the best scenario for this family of compounds?

Unique bladder delivery system of gemcitabine herolds remarkable response

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining first-line standard of care in mUC!

Chemo-IO establishes itself in the first-line treatment of bladder cancer

EV + Pembro as standard of care in first-line therapy of bladder cancer

Amazing new data in bladder cancer

New SoC in firstline bladder cancer

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Where does the future therapy go in renal cell carcinoma?

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of patients?

Belzutifan in later lines of therapy

Intermittent therapy also possible with TKIs

Belzutifan - whats next kidney cancer?

New mode of action in mRCC - ready for prime time?

Kidney cancer highlights at ESMO23

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - a new paradigm in operated NSCLC with ALK-fusion

Substantial improvement in local regional NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Scene is set for inductive immunotherapy

My highlights from ESMO 2023

ALINA - immediate change of practice!

Big improvements in early stage and a subset of metatstic NSCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Circulating DNA in AEGEAN trial

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

I miei punti salienti di ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

Les points forts de l'ESMO 2023

Evolving landscape of ADCs

ESMO2023-impact on everyday practice!

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Activating EGFR-mutation - what's coming up?

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

LIBRETO - a positive study, but was it necessary?

NRG fusions: a new drugable target?

My highlights from ESMO 2023

By unanimous decision and still the champion – docetaxel!

Amivantamab at progression? MARIPOSA-2 trial

Big improvements in early stage and a subset of metatstic NSCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

PAPILLON - bringing together therapy for the 1st line

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

Practice changing results on exon 20 insertion mNSCLC

MARIPOSA II: Trial and controversies

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Do ADCs have brain activity?

TROPION-Lung01: positive development

MARIPOSA: Trial and controversies

Changing treatment landscape in EGFR-mutated NSCLC

Does immunotherapy still have a place in EGFR-positive mNSCLC?

Treatment sequences for EGFR-mutated Patients

Substantial improvement in rare alterations

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Amivantamab upfront? MARIPOSA trial

Brain metastases – options to improve the systemic treatment

Amivantamab upfront? MARIPOSA trial

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Les points forts de l'ESMO 2023

Amivantamab at progression? MARIPOSA-2 trial

I miei punti salienti di ESMO 2023

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Quelles séquences thérapeutiques pour les patients EGFR mutés

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Impact of T-cell engagers in SCLC

A new option in relapsed SCLC

New hope for patients with SCLC

Tarlatamab in SCLC

Neue Hoffnung für Patienten mit SCLC

Precision oncology in CUP

New data on H&N Cancer

Evolution of the revolution - the RUBY trial

New data on sarkomas

PCO Therapeutics

First data on luveltamab in multiline treatment for endometrial cancer

Update on gynaecological cancers